Felicitas La Rosée

4PUBLICATIONS
8CO-AUTHORS
Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jul 28, 2023
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.

J Hammersen, S Birndt, K Döhner

|Jun 11, 2020
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.

F La Rosée, H C Bremer, I Gehrke

Pageof 1

Frequent Collaborators

4 joint publications

Paul La Rosée

2 joint publications

S Birndt

2 joint publications

P Reuken

1 joint publications

M M Rüthrich